Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AbbVie Ends Development Program with Halozyme After Phase 1 Study Failure of Humira Formulation

By Meg Snyder | November 22, 2016

AbbVie has discontinued a development program with biotechnology company Halozyme Therapeutics after a phase 1 study did not achieve its target results. 

Halozyme announced AbbVie’s discontinuation of the development program using Halozyme’s ENHANZE™ platform technology and the tumor necrosis factor alpha (TNF-alpha) target on Monday, November 21. The company said in a statement: “Halozyme and AbbVie will continue to work collaboratively to identify additional targets for co-development under their 2015 Global Collaboration and Licensing agreement. TNF-alpha was the first nominated target of nine included as part of the agreement.”

According to Fierce Biotech, “a spokesman confirmed that the drug in question [the TNF alpha target] was indeed a new formulation of AbbVie’s multibillion-dollar brand Humira (adalimumab) which started clinical testing in January. . . . AbbVie viewed the Enhanze formulation of Humira as a way to defend the $14 billion-a-year drug from future biosimilar competition.”

The exact reason for the “deficiencies” in the trial remain uncertain, as AbbVie has only said that the phase 1 study didn’t “meet the profile they had targeted.” 

The collaboration between the two companies began in June of 2015—wherein AbbVie promised Halozyme $23 million upfront and $130 million “in milestones on each of up to 9 programs” (a potential payoff amount of approximately $1.17 billion). 

In addition to its collaboration with AbbVie, Halozyme also partners with Roche, Baxalta, Pfizer, Janssen, and Lilly for its ENHANZE™ drug delivery platform. According to GEN News, “ENHANZE is based on Halozyme’s recombinant human hyaluronidase enzyme, which has been shown to remove traditional limitations on the volume of biologics that can be delivered subcutaneously.”

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE